Skip to content

Main Navigation

Singapore Era
  • Home
  • SEAPRWire
  • EQS
  • ACNNewswire
  • JCNNewswire
  • Contact

Categories

  • ACN Newswire
  • EQS Newswire
  • JCN Newswire
  • Top Story

Latest News

  • Tianyun International Announced 2022 Annual Results
  • Analogue Grows FY2022 Revenue and Contracts Awarded by 21.0% and 41.8% Respectively Defying Challenging Market Conditions
  • 天韵国际公布2022年全年业绩
  • 安乐工程2022全年收益及获授合约逆市增加21.0%及41.8%
  • EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong
  • 祖龙娱乐发布2022年度业绩

Links

  • YAHOO
  • NASDAQ
  • Bloomberg
  • Newswire
  • EastMud
  • AsiaEase
  • NetDace
  • HKBrowse
  • AccessTH
  • AseanTrend

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

January 27, 2023 jcn

TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline.

In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway based on the results from the Phase III Clarity AD confirmatory study. In Japan, Eisai submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. In China, Eisai has initiated submission of data for a BLA to the National Medical Products Administration (NMPA) of China in December 2022.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

*Protofibrils are large Aβ aggregated soluble species of 75-500 Kd.(1),(2)

(1) “Lecanemab Sweeps up Toxic AΒ Protofibrils, Catches Eyes of Trialists.” ALZFORUM, ALZFORUM, 21 Nov. 2021, bit.ly/3HzXXyE.
(2) Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2): e32014. doi: 10.1371/journal.pone.0032014. Epub 2012 Feb 15. PMID: 22355408; PMCID: PMC3280222.

For more information, visit www.eisai.com/news/2023/news202311.html.

Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswireapplication, authorization, eisai, marketing, submitted

Post navigation

SCIB Enforces Rights to Withdraw from Project
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
  • Home
  • About Us
  • Contact Us
  • Term of Use
  • RSS Feed
  • ACN Newswire
  • EQS Newswire
  • JCN Newswire
  • Top Story
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
Copyright ©2023 Singapore Era : Latest News & Events in Singapore.